HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LAIVUORI, H. Articles by KONTULA, K. Search for Related Content PubMed PubMed Citation Articles by LAIVUORI, H. Articles by KONTULA, K.

677 CT Polymorphism of the Methylenetetrahydrofolate Reductase Gene and Preeclampsia

From the Departments of Obstetrics and Gynecology and Medicine, Helsinki University Central Hospital, Helsinki, Finland.

Address reprint requests to: Hannele Laivuori, MD Helsinki University Central Hospital Department of Obstetrics and Gynecology Box 140 00029 HYKS Helsinki Finland E-mail: hannele.laivuori{at}pp.fimnet.fi

Objective: To evaluate C to T substitution at nucleotide 677 of N⁵,N¹⁰-methylenetetrahydrofolate reductase gene in women with prior preeclamptic or normotensive pregnancies.

Methods: Methylenetetrahydrofolate reductase genotypes were determined in 113 Finnish women with preeclamptic first pregnancies and 103 controls with one or more normotensive pregnancies, using polymerase chain reaction and restriction enzyme analysis. Preeclampsia was defined as severe in 100 women who fulfilled one or more of the subsequent criteria: systolic blood pressure (BP) at least 160 mmHg, diastolic BP at least 110 mmHg, or proteinuria at least 2 g per 24-hour urine collection.

Results: There were no significant differences in prevalences of the methylenetetrahydrofolate reductase genotypes (CC, CT, and TT) between groups (57%, 40%, and 3% in the preeclamptic group and 54%, 39%, and 7%, respectively, in controls). The frequency of the T677 allele was 0.23 in the preeclamptic group and 0.26 in the control group (difference 0.03; 95% confidence interval -0.08, 0.14; P = .51). Our sample had 60% power to detect a difference of the allele frequencies similar to that (0.12) reported previously. The result was similar when analysis was restricted to patients with severe preeclampsia (T677 allele frequency 0.22).

Conclusion: A carrier status for the T677 allele of the methylenetetrahydrofolate reductase gene does not predispose to preeclampsia, at least in the Finnish population.

This article has been cited by other articles:

				J. Lin and P. August Genetic Thrombophilias and Preeclampsia: A Meta-Analysis Obstet. Gynecol., January 1, 2005; 105(1): 182 - 192. [Abstract] [Full Text] [PDF]

				D. Prasmusinto, S. Skrablin, C. Hofstaetter, R. Fimmers, and K. van der Ven The Methylenetetrahydrofolate Reductase 677 C->T Polymorphism and Preeclampsia in Two Populations Obstet. Gynecol., June 1, 2002; 99(6): 1085 - 1092. [Abstract] [Full Text] [PDF]

				L. A. HEFLER, C. B. TEMPFER, and A. R. GREGG Polymorphisms Within the Interleukin-1{beta} Gene Cluster and Preeclampsia Obstet. Gynecol., May 1, 2001; 97(5): 664 - 668. [Abstract] [Full Text] [PDF]